The research, led by Wanqiu Huang and Jinjing Ni together with colleagues at Shanghai Jiao Tong University School of Medicine and collaborating institutions, focuses on a histone modification known as H2BK16ac. This tag refers to the acetylation of lysine 16 on histone H2B, one of the proteins around which DNA is wound. Acetylation of histone tails generally loosens the chromatin structure, making genes more accessible to the transcription machinery. When the researchers examined macrophages infected with Salmonella, they found that this acetylation mark on H2BK16 was actively removed. The deacetylation was carried out by two enzymes, HDAC1 and HDAC3, which strip acetyl groups from histones and thereby tighten chromatin at specific genomic locations.

The consequence of this chromatin tightening was the transcriptional silencing of a gene called Id3, which encodes Inhibitor of Differentiation 3. ID3 is a member of the helix-loop-helix protein family and is known to influence the behavior of various immune cells, but its role in macrophage-mediated antibacterial defense had not been clearly defined. The new study shows that when Salmonella drives H2BK16 deacetylation through HDAC1 and HDAC3, the Id3 gene is switched off, and macrophages lose an important layer of antimicrobial capacity. This finding places ID3 at the center of an infection-induced epigenetic pathway that directly shapes how macrophages respond to bacterial challenge.

To establish that ID3 genuinely strengthens macrophage defenses, the team performed both loss-of-function and gain-of-function experiments. When ID3 was removed or reduced, macrophages showed a weakened inflammatory response and diminished antimicrobial activity. Conversely, when ID3 was increased, macrophages displayed enhanced antibacterial function. These results demonstrate that ID3 is not a passive bystander in the infection response but an active contributor to the macrophage arsenal against invading bacteria.

The mechanistic heart of the study lies in how ID3 controls the expression of another protein, Z-DNA binding protein 1, commonly abbreviated as ZBP1. ZBP1 is a sensor that recognizes certain nucleic acid structures and participates in immune signaling. The researchers discovered that a transcription factor called E2A binds to the ZBP1 gene and represses its transcription. ID3 counteracts this repression by sequestering E2A, effectively pulling it away from the ZBP1 promoter. With E2A occupied by ID3, the ZBP1 gene is free to be transcribed, and macrophages maintain robust ZBP1 expression. This sequestration mechanism reveals a precise molecular handoff in which ID3 acts as a decoy to relieve transcriptional braking on an antimicrobial effector gene.

The in vivo relevance of this circuit was tested in mice engineered to lack Id3 specifically in myeloid cells, the lineage that includes macrophages. When these myeloid-specific Id3-deficient mice were infected with Salmonella, they carried higher bacterial burdens and suffered greater pathological damage than control animals. This outcome confirms that the ID3-ZBP1 axis is not merely a cell-culture curiosity but a functional component of antibacterial immunity in living organisms. The data suggest that the integrity of this epigenetic pathway determines how effectively the host can contain systemic bacterial spread.

Perhaps the most translational aspect of the study involves a pharmacological intervention. The researchers treated infected mice with MS-275, an inhibitor of histone deacetylases that targets HDAC1 among other class I enzymes. Administration of MS-275 restored the H2BK16ac mark, reactivated the Id3 gene, and thereby rebuilt the ID3-ZBP1 signaling axis. In practical terms, the drug reversed the epigenetic silencing that Salmonella had imposed on macrophages. Mice receiving this treatment showed amelioration of systemic Salmonella infection, demonstrating that pharmacologically reopening the chromatin at Id3 can translate into meaningful protection against bacterial disease.

These findings carry several implications for the broader field of infection biology. First, they establish that pathogens do not merely evade immune detection; they actively reshape the epigenetic landscape of host immune cells to disable specific defense genes. The Salmonella-driven deacetylation of H2BK16 represents a concrete example of how bacterial infection can hijack the host’s own chromatin-modifying enzymes to silence protective transcriptional programs. Second, the study identifies ID3 as a previously underappreciated regulator of macrophage immunity, bridging histone acetylation status to the expression of a nucleic acid sensor involved in antimicrobial signaling. Third, the demonstration that an HDAC inhibitor can restore this axis in vivo suggests a therapeutic window in which epigenetic drugs, originally developed for oncology, might be repurposed as adjunct treatments for severe bacterial infections.

The work also raises questions that will likely drive future research. It remains to be seen whether other pathogens employ similar strategies to silence Id3 or related immune regulators through histone deacetylation. The precise kinetics of HDAC1 and HDAC3 recruitment to the Id3 locus during infection, and whether additional chromatin marks cooperate with H2BK16ac in this process, are areas that warrant deeper investigation. Furthermore, because ZBP1 has been implicated in antiviral as well as antibacterial pathways, the ID3-E2A-ZBP1 circuit could have relevance beyond Salmonella, potentially influencing how macrophages respond to a wider spectrum of infectious threats. The study by Huang, Ni, and colleagues thus opens a new line of inquiry into how epigenetic therapies might bolster innate immunity at a time when antibiotic resistance continues to limit conventional treatment options.

Subject of Research: Infection-driven epigenetic regulation of macrophage innate immunity through the H2BK16ac-ID3-ZBP1 axis

Article Title: Infection-driven epigenetics modulate macrophage innate immunity through the H2BK16ac-ID3-ZBP1 axis

Article References: Huang, W., Ni, J., Tang, H., Chen, Y., Zhou, T., Yu, J., Wang, Z., Wen, B., Yan, H., Wang, C., Tao, J., Lu, J., Zhao, G.-P., Wang, D., & Yao, Y.-F. (2026). Infection-driven epigenetics modulate macrophage innate immunity through the H2BK16ac-ID3-ZBP1 axis. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06432-6

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06432-6

Keywords: macrophage, innate immunity, epigenetics, histone acetylation, H2BK16ac, ID3, ZBP1, Salmonella, HDAC1, HDAC3, E2A, MS-275

Glioma is the most common malignant primary brain tumor in adults, and its most aggressive form, glioblastoma, carries a median survival measured in months rather than years. The therapeutic arsenal remains painfully thin: surgical resection, radiation, and the chemotherapy drug temozolomide extend life only modestly, and the blood-brain barrier blocks many otherwise promising compounds from ever reaching the tumor. Against this backdrop, scientists have increasingly turned to cell death programs as therapeutic levers. Apoptosis, the quiet and orderly form of cell suicide, has long been the target of conventional cancer drugs, but tumors routinely evolve resistance to it. Pyroptosis, by contrast, is loud, inflammatory, and lytic: cells swell, rupture, and release their contents, simultaneously destroying the tumor cell and sounding an immune alarm.

The molecular machinery of pyroptosis centers on the gasdermin family of proteins. When enzymes such as caspases cleave a gasdermin protein, the released fragment migrates to the cell membrane and punches oligomeric pores into it. The cell loses its ionic balance, swells with water, and ultimately bursts, spilling damage-associated molecular patterns and inflammatory cytokines such as interleukin-1 beta into the tumor microenvironment. One family member in particular, gasdermin E, or GSDME, has attracted intense interest because it can be cleaved by caspase-3, the very executioner enzyme of apoptosis. In principle, this creates a molecular switch: a stimulus that begins as apoptotic can be diverted into pyroptosis when GSDME is present, converting a silent death into an immunostimulatory event capable of reshaping the tumor’s immune landscape.

Recognizing this potential, Hanwen Lu and Zhanxiang Wang of the First Affiliated Hospital of Xiamen University and their collaborators set out to do something that had not been done systematically before: build a dedicated library of pyroptosis-inducing compounds and filter it through the unforgiving realities of brain tumor pharmacology. The team assembled their library by combining commercially available pyroptosis inducers with candidates harvested from an exhaustive mining of the PubMed and Web of Science literature. But identifying a molecule that triggers pyroptosis in a dish is only the first hurdle. For a brain cancer drug, the compound must also survive the gauntlet of drug-likeness filters and, crucially, cross the blood-brain barrier, the tightly sealed endothelial lining that excludes the vast majority of small molecules from the central nervous system.

To solve this, the researchers applied a sequential computational and pharmacological funnel. First came Lipinski’s rule of five, the classic checklist of molecular weight, hydrogen-bond donors and acceptors, and lipophilicity that predicts oral absorbability. Next, they used predictive models of blood-brain barrier permeability, followed by central nervous system multiparameter optimization scoring, a more sophisticated metric that balances multiple physicochemical properties to estimate the likelihood that a molecule will achieve adequate brain exposure without unacceptable side effects. Stringent descriptor-based criteria narrowed the field further, and a final round of pharmacological curation and literature vetting elevated a short list of priority candidates. Rising to the top of that list was diacerein, a drug oncologists had never seriously considered but rheumatologists have prescribed for years.

Diacerein is an anthraquinone derivative that works as a slow-acting anti-osteoarthritic agent, traditionally understood to inhibit interleukin-1 beta signaling in cartilage. Its established safety profile, oral availability, and favorable predicted brain penetration made it an attractive repurposing candidate. In laboratory experiments, the team found that diacerein significantly inhibited the proliferation of glioma cells and suppressed tumor growth in animal models. But the mechanism they uncovered was far more interesting than simple growth arrest. Treatment with diacerein activated caspase-3, the canonical apoptotic executioner, and simultaneously triggered the cleavage of GSDME, the gasdermin protein that converts caspase-3 activity into pyroptotic membrane rupture. In other words, the drug appeared to push glioma cells down a hybrid death pathway that begins with apoptosis and culminates in pyroptosis-like lysis.

To confirm that GSDME was not merely a bystander in this process, the researchers performed loss-of-function experiments. When they knocked down GSDME in glioma cells, the cytotoxic punch of diacerein was substantially blunted: cell viability recovered, and the drug’s killing efficiency dropped. This partial rescue demonstrates that GSDME is functionally required for a significant share of diacerein-induced glioma cell death, anchoring the drug’s effect in the pyroptotic pathway the screen was designed to find. The team also traced changes in inflammation-related signaling, observing reduced activity along the interleukin-1 beta, NF-kappa B, and phosphorylated STAT3 axes. Because these pathways sit at the heart of macrophage-mediated inflammation, the authors suggest the drug may also alter macrophage-related immune dynamics within the tumor microenvironment in living animals, a possibility with major implications given the prominent role of tumor-associated macrophages in glioma immunosuppression.

The implications extend beyond a single molecule. The study validates a repurposing strategy that begins with a cell death mechanism rather than a molecular target, then filters candidate drugs through the pharmacological constraints of the diseased tissue. This pyroptosis-oriented pipeline could in principle be rerun for other cancers of the central nervous system, or adapted to other lytic death programs such as necroptosis and ferroptosis. It also illustrates the growing power of literature mining as a discovery tool: by systematically extracting pyroptosis-inducing activity from thousands of published pharmacological studies, the team assembled a candidate pool that no single laboratory’s compound collection would have contained. The approach effectively converts the accumulated knowledge of pharmacology into a searchable, filterable database of mechanism-directed therapeutics.

Considerable work remains before diacerein could reach glioma patients. The doses used in laboratory and animal studies may not map directly onto the exposures achievable and tolerable in humans, and the authors evaluated brain exposure using liquid chromatography-tandem mass spectrometry methods developed specifically for this study, but clinical pharmacokinetics in glioma patients, where the blood-brain barrier is often locally disrupted yet heterogeneously intact, will need dedicated investigation. The precise molecular target through which diacerein initiates caspase-3 activation in glioma cells also remains to be fully defined, and the immunological consequences of triggering pyroptosis inside the brain, an organ exquisitely sensitive to inflammation, must be carefully characterized. Nevertheless, the fact that diacerein is already an approved, well-characterized medicine with a known safety record could substantially shorten the path from bench to bedside, potentially through investigator-initiated clinical trials in recurrent glioma, where new options are desperately needed and the regulatory bar for repurposed drugs is lower than for entirely novel agents.

For a disease that has defeated nearly every therapeutic innovation thrown at it, the idea that an arthritis pill sitting in pharmacy shelves worldwide might recruit the immune system against glioma through gasdermin pores is the kind of unexpected twist that drug repurposing was made for. The Xiamen team’s work provides both a concrete candidate and a reusable discovery framework, suggesting that the next breakthrough in brain cancer may not come from a molecule designed from scratch, but from an old drug viewed through an entirely new biological lens.

Subject of Research: Pyroptosis-oriented drug repurposing identifies diacerein as a therapeutic candidate for glioma

Article Title: Pyroptosis-oriented drug discovery identifies diacerein as a promising therapeutic candidate for glioma

Article References: Lu, H., & Wang, Z. (2026). Pyroptosis-oriented drug discovery identifies diacerein as a promising therapeutic candidate for glioma. BMC Medicine. https://doi.org/10.1186/s12916-026-05187-y

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05187-y

Keywords: glioma, diacerein, pyroptosis, GSDME, caspase-3, drug repurposing, blood-brain barrier, immune microenvironment, macrophage, NF-kappa B, IL-1 beta, BMC Medicine